[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 19 days · First seen · Last updated

Synthomer earnings and stock performance

Overview

In mid‑July 2026, Synthomer plc’s shares broke above their 200‑day moving average, climbing to GBX 84.22 before closing at GBX 82. Analyst houses raised price targets, and insider Lily Liu bought a sizable block of shares. The same day, Spyre Therapeutics also saw a price jump after analyst upgrades, but the focus remained on Synthomer’s market momentum.

A few weeks later, Synthomer reported strong first‑half 2026 results, with revenue up 6.7% and EBITDA improving to a 10.1% margin. The company lifted its full‑year guidance, citing growth in specialty products, cost‑saving measures, and better cash generation. Management highlighted progress in intumescent coatings, sustainable CLIMA products, and medical adhesives, while noting temporary margin pressures at sites in the Netherlands and Texas. Pending divestments were expected to raise £150‑200 million, reinforcing the upbeat outlook.

Entities

Symbotic · Context Therapeutics · Iain Torrens · Synthomer plc

Timeline

  1. 21 days ago

    [BUSINESS] 3 sources
    Context Therapeutics and Symbotic Miss Quarterly Earnings Expectations

    Context Therapeutics posted a $0.05‑per‑share earnings miss, while Symbotic fell short by $0.04 per share despite revenue growth, as both Nasdaq firms reported quarterly results.

  2. about 1 month ago

    [BUSINESS] 2 sources
    Synthomer and Spyre Therapeutics stocks rise above key moving averages amid analyst upgrades

    Synthomer broke above its 200‑day average as analysts raised targets, while Spyre Therapeutics rose over 5% with analysts lifting price goals to $120‑$101.

Sources

mommygearest.com · seekingalpha.com · stocknews.com